SCOTTSDALE, Ariz., July 9 /PRNewswire/ -- MedApps, Inc. announces the granting of regulatory clearance for over-the-counter use of the MedApps D-PAL Remote Patient Monitoring System for Diabetes by the U.S. Food and Drug Administration (FDA).
D-PAL presents a revolutionary new way for people with diabetes to automatically transfer their daily glucose readings from their D-PAL integrated glucose monitors directly to a central server for records storage and review by healthcare professionals. D-PAL currently combines with the Polymap Polytel(R) device which connects to the LifeScan(R) OneTouch(R) Ultra(R) and sends the data via Bluetooth(R) (wireless) to the patient’s cell phone (acting as a “Hub”) and transmits the information to the central server in near real-time. D-PAL is the first of a series of medical devices that integrates with the MedApps System and enables patients with chronic diseases to lead more active lifestyles. Additional integrated devices will include scales, blood pressure monitors, spirometers, pulse oximeters, ECG, and a variety of implantable devices such as pacemakers.
Pre-established thresholds are set for each patient by their healthcare provider(s). When a reading occurs outside of these thresholds, an alert may occur and the patient may be contacted using a pre-determined mode. One such mode is an interactive voice response system which can qualify additional behavioral information by asking questions such as, “Have you exercised today?” or “Have you taken your medication?” The responses to these questions, combined with previously collected biometric data, can give healthcare professionals greater insight into a patient’s health.
The MedApps Telemedicine 2.0 Wireless System, allows medical providers to monitor trends in their patients’ health with accurate, timely readings. Healthcare professionals and patient management companies have greater accessibility to better information and no longer have to rely on patients to submit their own readings, while the patient, in turn, is encouraged to live a more active lifestyle. As patients lose mobility, they must curtail daily activities, in essence giving “control” of their lives to their disease. This loss of control signals a downward spiral toward immobilization, inpatient encounters, and costly ER visits. MedApps helps stabilize patient treatments, allows timely interventions, and gives patients more control over their diseases.
About MedApps, Inc.
MedApps, Inc. is headquartered in Scottsdale, Arizona, and was founded in July 2006. MedApps is a current mentor participant in the prestigious Arizona State University (ASU) Technopolis Mentoring Program and was recently named to the Fierce Health IT Top 10 Healthcare IT Innovators for 2007, a notable distinction among healthcare IT startups. http://www.fiercehealthit.com/innovators/2007/medapps
MedApps is partnering and working with major medical device manufacturers, telecom companies, medical software companies, chip and component manufacturers and healthcare organizations to introduce its Telemedicine 2.0 Solution on a national level.
The initial launch of the MedApps System will begin with D-PAL(TM) to monitor diabetes, followed by H-PAL(TM) (scale and blood pressure monitor) for congestive heart failure (CHF), A-PAL(TM) (spirometer) for asthma and COPD, T-PAL(TM) for tremor and Parkinson’s disease and BlueMICS(TM) for communication with implantable devices (pacemakers, defibrillators, loop recorders, etc.).
For more information, call 1-888-US-MEDAPPS or visit our website at http://www.medapps.net
MEDAPPS, INC. - MEDIA CONTACTS Catie Bossard Media Director, MedApps, Inc. catie.bossard@medapps.net 1-888-US-MEDAPPS x111 Kent E. Dicks President, MedApps, Inc. kent.dicks@medapps.net 1-888-US-MEDAPPS x110 1-602-738-7530
MedApps, Inc.
CONTACT: Catie Bossard, Media Director, ext. 111,catie.bossard@medapps.net, or Kent E. Dicks, President, ext. 110, or1-602-738-7530, kent.dicks@medapps.net, both of MedApps, Inc.,+1-888-US-MEDAPPS
Web site: http://www.medapps.net/
